Multiple Sclerosis, Relapsing-Remitting Clinical Trial
Official title:
Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS)
affecting roughly 900,000 people in the United States that frequently results in impaired
mobility. The majority of people with MS express that impaired mobility the most difficult
aspect of living with the disease. Ataxia is one aspect of impaired mobility experienced by
approximately 80% of persons with MS. Despite $9 billion in drug costs to patients with MS in
the U.S., in 2012 alone, standard pharmacological treatment for MS is ineffective in
restoring mobility and decreasing ataxia. The PI designed a targeted ballet program requiring
motor learning of complex movements that mitigated ataxia and improved balance in patients
with MS in a pilot study. The improvements obtained were approximately five times larger than
those reported by other physical rehabilitation interventions. However, understanding these
changes requires determining whether there are underlying changes in the brain after
participation in the targeted ballet program.
This project involves persons with mild-to-moderate MS that present ataxia in their movement.
We will compare the brain connectivity of participants in the targeted ballet program before
and after the 16-week, twice per week, hourly participation intervention. Brain images will
be obtained with magnetic resonance imaging while each participant rests with the eyes open.
As a secondary outcome, measures of movement quality, ataxia, and balance will be taken to
better understand the effects of the targeted ballet program on motor function, wellness, and
the brains of persons with mild to moderate MS. Test on movement will include a 10 meter walk
with motion tracking, a balance test using a force plate, and clinical tests of ataxia,
balance, and walking speed. We will also assess changes in wellness with standard
questionnaires.
Multiple sclerosis (MS) is an autoimmune-mediated disease with brain demyelination and axonal
loss that result in impaired mobility, which affects an estimated 75% of people with MS and
is reported as the most difficult aspect of living with MS. An estimated 900,000 people in
the U.S. suffer from MS, which has no known cure. In 2012 alone, drug costs to patients with
MS in the U.S. were $9 billion. Despite the high costs, pharmacological interventions do not
induce myelination so motor impairments persist. The PI designed a ballet-based program for
complex motor learning delivered in a group setting. Our previous work provides evidence that
the targeted ballet program increased balance and walking scores by 42% and decreased
clinical ataxia scores by 58% over a period of 16 weeks and 32 hours of instruction. However,
understanding these changes requires determining whether there are underlying changes in the
brain after participation in the targeted ballet program.
The goal of this proposal is to provide evidence of improvements in brain connectivity
measures after participation in the targeted ballet program in persons with MS. As secondary
outcomes, we will assess motor function and wellness after participation in the targeted
ballet program in persons with MS.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02861014 -
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
|
Phase 3 | |
Terminated |
NCT01435993 -
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
|
Phase 1 | |
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02410200 -
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
|
Phase 2 | |
Completed |
NCT03975413 -
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
|
||
Completed |
NCT05080270 -
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
|
Early Phase 1 | |
Completed |
NCT01116427 -
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01108887 -
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmartâ„¢.
|
N/A | |
Completed |
NCT01141751 -
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
|
N/A | |
Completed |
NCT00097331 -
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01909492 -
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
|
||
Completed |
NCT04121221 -
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
|
Phase 3 | |
Withdrawn |
NCT04880577 -
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT05290688 -
Cellular microRNA Signatures in Multiple Sclerosis
|
N/A | |
Completed |
NCT04528121 -
Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT04002934 -
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05019248 -
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
|
||
Completed |
NCT04580381 -
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
|
||
Completed |
NCT00071838 -
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 2 |